Wednesday, May 9, 2012

Leukemia - Table of Contents alert Volume 26 Issue 5

TABLE OF CONTENTS

Volume 26, Issue 5 (May 2012)

In this issue
How To Manage…
Original Articles
Letters to the Editor
Corrigendum

Also new
AOP

Advertisement


BD Reagents for Blood Cell Disorders
Part of the building blocks to support patient care for blood cell disorders, BD Biosciences reagents provide a full spectrum of color choices, allowing you to analyze multiple parameters simultaneously and access a whole new world of information and insight. Welcome to a more colorful world(sm). bdbiosciences.com/go/color
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Subscribe
Advertisement
Why Blood Cancer Journal is the journal for your research

*Fully open access: maximum visibility worldwide
*Editorial: Peer reviewed by key editorial team and quick turnaround
*Impact: now indexed by Thomson Reuters ISI for Impact Factor

For the full Guide to Authors click here.
 

How To Manage…

Top

How to manage high-risk acute myeloid leukemia

E H Estey

Leukemia 2012 26: 861-869; advance online publication, November 25, 2011; 10.1038/leu.2011.317

Abstract | Full Text

How to manage polycythemia vera

F Passamonti

Leukemia 2012 26: 870-874; advance online publication, December 9, 2011; 10.1038/leu.2011.334

Abstract | Full Text

How to manage essential thrombocythemia

G Finazzi

Leukemia 2012 26: 875-882; advance online publication, November 4, 2011; 10.1038/leu.2011.306

Abstract | Full Text

Original Articles

Top

MOLECULAR TARGETS FOR THERAPY

Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts

Y Tabe, L Jin, K Iwabuchi, R-Y Wang, N Ichikawa, T Miida, J Cortes, M Andreeff and M Konopleva

Leukemia 2012 26: 883-892; advance online publication, October 18, 2011; 10.1038/leu.2011.291

Abstract | Full Text

ACUTE LEUKEMIAS

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

D A Pollyea, H E Kohrt, L Gallegos, M E Figueroa, O Abdel-Wahab, B Zhang, S Bhattacharya, J Zehnder, M Liedtke, J R Gotlib, S Coutre, C Berube, A Melnick, R Levine, B S Mitchell and B C Medeiros

Leukemia 2012 26: 893-901; advance online publication, October 28, 2011; 10.1038/leu.2011.294

Abstract | Full Text

Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia

E Ellinghaus, M Stanulla, G Richter, D Ellinghaus, G te Kronnie, G Cario, G Cazzaniga, M Horstmann, R Panzer Grümayer, H Cavé, J Trka, O Cinek, A Teigler-Schlegel, A ElSharawy, R Häsler, A Nebel, B Meissner, T Bartram, F Lescai, C Franceschi, M Giordan, P Nürnberg, B Heinzow, M Zimmermann, S Schreiber, M Schrappe and A Franke

Leukemia 2012 26: 902-909; advance online publication, November 11, 2011; 10.1038/leu.2011.302

Abstract | Full Text

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia

E McCormack, I Haaland, G Venås, R B Forthun, S Huseby, G Gausdal, S Knappskog, D R Micklem, J B Lorens, Ø Bruserud and B T Gjertsen

Leukemia 2012 26: 910-917; advance online publication, November 8, 2011; 10.1038/leu.2011.315

Abstract | Full Text

The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis–relapse samples of precursor B-cell acute lymphoblastic leukemia

C E de Bock, A Ardjmand, T J Molloy, S M Bone, D Johnstone, D M Campbell, K L Shipman, T M Yeadon, J Holst, M D Spanevello, G Nelmes, D R Catchpoole, L F Lincz, A W Boyd, G F Burns and R F Thorne

Leukemia 2012 26: 918-926; advance online publication, November 25, 2011; 10.1038/leu.2011.319

Abstract | Full Text

Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts

G Fuka, H-P Kantner, R Grausenburger, A Inthal, E Bauer, G Krapf, U Kaindl, M Kauer, M N Dworzak, D Stoiber, O A Haas and R Panzer-Grümayer

Leukemia 2012 26: 927-933; advance online publication, November 18, 2011; 10.1038/leu.2011.322

Abstract | Full Text

Landscape of TET2 mutations in acute myeloid leukemia

S Weissmann, T Alpermann, V Grossmann, A Kowarsch, N Nadarajah, C Eder, F Dicker, A Fasan, C Haferlach, T Haferlach, W Kern, S Schnittger and A Kohlmann

Leukemia 2012 26: 934-942; advance online publication, November 25, 2011; 10.1038/leu.2011.326

Abstract | Full Text

MYELODYSPLASIAS

Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment

M Y Follo, D Russo, C Finelli, S Mongiorgi, C Clissa, C Filì, C Colombi, M Gobbi, L Manzoli, M Piazzi, A M Martelli and L Cocco

Leukemia 2012 26: 943-950; advance online publication, October 28, 2011; 10.1038/leu.2011.300

Abstract | Full Text

CHRONIC MYELOPROLIFERATIVE NEOPLASIAS

An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis

C Teodosio, A C García-Montero, M Jara-Acevedo, I Álvarez-Twose, L Sánchez-Muñoz, J Almeida, J M Morgado, A Matito, L Escribano and A Orfao

Leukemia 2012 26: 951-958; advance online publication, November 4, 2011; 10.1038/leu.2011.293

Abstract | Full Text

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase

F J Giles, H M Kantarjian, P D le Coutre, M Baccarani, F-X Mahon, R E Blakesley, N J Gallagher, K Gillis, S L Goldberg, R A Larson, A Hochhaus and O G Ottmann

Leukemia 2012 26: 959-962; advance online publication, December 13, 2011; 10.1038/leu.2011.355

Abstract | Full Text

CHRONIC LYMPHOCYTIC LEUKEMIA

Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases

R M Linka, S L Risse, K Bienemann, M Werner, Y Linka, F Krux, C Synaeve, R Deenen, S Ginzel, R Dvorsky, M Gombert, A Halenius, R Hartig, M Helminen, A Fischer, P Stepensky, K Vettenranta, K Köhrer, M R Ahmadian, H-J Laws, B Fleckenstein, H Jumaa, S Latour, B Schraven and A Borkhardt

Leukemia 2012 26: 963-971; advance online publication, January 6, 2012; 10.1038/leu.2011.371

Abstract | Full Text

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium

W Wiktor-Jedrzejczak, C Dearden, L de Wreede, A van Biezen, L Brinch, V Leblond, M Brune, L Volin, M Kazmi, A Nagler, J Schetelig, T de Witte and P Dreger on behalf of the EBMT Chronic Leukemia Working Party

Leukemia 2012 26: 972-976; advance online publication, November 25, 2011; 10.1038/leu.2011.304

Abstract | Full Text

STEM CELLS

Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib

J J W M Janssen, W Deenik, K G M Smolders, B J van Kuijk, W Pouwels, A Kelder, J J Cornelissen, G J Schuurhuis and G J Ossenkoppele

Leukemia 2012 26: 977-984; advance online publication, December 9, 2011; 10.1038/leu.2011.347

Abstract | Full Text

MINIMAL RESIDUAL DISEASE

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

E Weisberg, A K Azab, P W Manley, A L Kung, A L Christie, R Bronson, I M Ghobrial and J D Griffin

Leukemia 2012 26: 985-990; advance online publication, December 20, 2011; 10.1038/leu.2011.360

Abstract | Full Text

IMMUNOLOGY

Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL)

C Buechele, T Baessler, S Wirths, J U Schmohl, B J Schmiedel and H R Salih

Leukemia 2012 26: 991-1000; advance online publication, November 8, 2011; 10.1038/leu.2011.313

Abstract | Full Text

SENSITIVITY AND RESISTANCE TO THERAPY

IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase

A B A Laranjeira, J F de Vasconcellos, L Sodek, M C Spago, M C Fornazim, L G Tone, S R Brandalise, A E Nowill and J A Yunes

Leukemia 2012 26: 1001-1011; advance online publication, October 18, 2011; 10.1038/leu.2011.289

Abstract | Full Text

ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES

CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12

M A Mulaw, A J Krause, A J Deshpande, L F Krause, A Rouhi, R La Starza, A Borkhardt, C Buske, C Mecucci, W-D Ludwig, C Lottaz and S K Bohlander

Leukemia 2012 26: 1012-1019; advance online publication, November 8, 2011; 10.1038/leu.2011.307

Abstract | Full Text

APOPTOSIS

RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis

S Löder, M Fakler, H Schoeneberger, S Cristofanon, J Leibacher, N Vanlangenakker, M J M Bertrand, P Vandenabeele, I Jeremias, K-M Debatin and S Fulda

Leukemia 2012 26: 1020-1029; advance online publication, December 16, 2011; 10.1038/leu.2011.353

Abstract | Full Text

ANIMAL MODELS

Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML

M Schemionek, T Spieker, L Kerstiens, C Elling, M Essers, A Trumpp, W E Berdel, C Müller-Tidow and S Koschmieder

Leukemia 2012 26: 1030-1037; advance online publication, December 23, 2011; 10.1038/leu.2011.366

Abstract | Full Text

Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis

T Oki, J Kitaura, N Watanabe-Okochi, K Nishimura, A Maehara, T Uchida, Y Komeno, F Nakahara, Y Harada, T Sonoki, H Harada and T Kitamura

Leukemia 2012 26: 1038-1045; advance online publication, November 25, 2011; 10.1038/leu.2011.328

Abstract | Full Text

LYMPHOMA

Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma

S M Ansell, H Tang, P J Kurtin, P A Koenig, G S Nowakowski, D A Nikcevich, G D Nelson, Z Yang, D M Grote, S C Ziesmer, P T Silberstein, C Erlichman and T E Witzig

Leukemia 2012 26: 1046-1052; advance online publication, October 21, 2011; 10.1038/leu.2011.297

Abstract | Full Text

Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells

P Amé-Thomas, J Le Priol, H Yssel, G Caron, C Pangault, R Jean, N Martin, T Marafioti, P Gaulard, T Lamy, T Fest, G Semana and K Tarte

Leukemia 2012 26: 1053-1063; advance online publication, October 21, 2011; 10.1038/leu.2011.301

Abstract | Full Text

The miRNA-17~92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation

E Rao, C Jiang, M Ji, X Huang, J Iqbal, G Lenz, G Wright, L M Staudt, Y Zhao, T W McKeithan, W C Chan and K Fu

Leukemia 2012 26: 1064-1072; advance online publication, November 25, 2011; 10.1038/leu.2011.305

Abstract | Full Text

MYELOMA

Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC

T Holien, T K Våtsveen, H Hella, C Rampa, G Brede, L A G Grøseth, M Rekvig, M Børset, T Standal, A Waage and A Sundan

Leukemia 2012 26: 1073-1080; advance online publication, September 23, 2011; 10.1038/leu.2011.263

Abstract | Full Text

Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells

S Lamorte, S Ferrero, S Aschero, L Monitillo, B Bussolati, P Omedè, M Ladetto and G Camussi

Leukemia 2012 26: 1081-1090; advance online publication, October 25, 2011; 10.1038/leu.2011.290

Abstract | Full Text

Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research

A Mahindra, M E Kalaycio, J Vela-Ojeda, D H Vesole, M-J Zhang, P Li, J R Berenson, J M Bird, A Dispenzieri, J L Gajewski, R P Gale, L Holmberg, S Kumar, R A Kyle, H M Lazarus, S Lonial, J Mikhael, G A Milone, R Munker, R Nath, S Saccaro, L Bik To, D T Vogl, B Wirk and P Hari

Leukemia 2012 26: 1091-1097; advance online publication, November 1, 2011; 10.1038/leu.2011.312

Abstract | Full Text

CD29 expressed on plasma cells is activated by divalent cations and soluble CD106 contained in the bone marrow plasma: refractory activation is associated with enhanced proliferation and exit of clonal plasma cells to circulation in multiple myeloma patients

E Martínez-Viñambres, J A García-Trujillo, E Rodríguez-Martín, L M Villar, J Coll and E Roldán

Leukemia 2012 26: 1098-1105; advance online publication, December 2, 2011; 10.1038/leu.2011.335

Abstract | Full Text

Letters to the Editor

Top

DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

K H Metzeler, A Walker, S Geyer, R Garzon, R B Klisovic, C D Bloomfield, W Blum and G Marcucci

Leukemia 2012 26: 1106-1107; advance online publication, November 29, 2011; 10.1038/leu.2011.342

Full Text

Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34

K Shedden, Y Li, P Ouillette and S N Malek

Leukemia 2012 26: 1108-1110; advance online publication, December 20, 2011; 10.1038/leu.2011.361

Full Text

NPM-MLF1 synergizes with Npm haploinsufficiency to enhance myeloid progenitor activity

W-H Lee, S Salek-Ardakani, P P Pandolfi, H J M Brady, J de Boer and O Williams

Leukemia 2012 26: 1110-1112; advance online publication, December 23, 2011; 10.1038/leu.2011.365

Full Text

Stromal cells and CD40 ligand (CD154) alter the miRNome and induce miRNA clusters including, miR-125b/miR-99a/let-7c and miR-17-92 in chronic lymphocytic leukaemia

S Willimott and S D Wagner

Leukemia 2012 26: 1113-1116; advance online publication, October 25, 2011; 10.1038/leu.2011.299

Full Text

β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome–aggresome–autophagosome–lysosome pathway

K Sukhdeo, M Mani, T Hideshima, K Takada, V Pena-Cruz, G Mendez, S Ito, K C Anderson and D R Carrasco

Leukemia 2012 26: 1116-1119; advance online publication, November 4, 2011; 10.1038/leu.2011.303

Full Text

Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies

S Sinha, M A Gertz, M Q Lacy, A Dispenzieri, S R Hayman, F K Buadi, D Dingli, I N Micallef, W J Hogan, D A Gastineau, S V Rajkumar and S K Kumar

Leukemia 2012 26: 1119-1122; advance online publication, October 28, 2011; 10.1038/leu.2011.308

Full Text

Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice

C R Moore, Y Liu, C Shao, L R Covey, H C Morse, III and P Xie

Leukemia 2012 26: 1122-1127; advance online publication, October 28, 2011; 10.1038/leu.2011.309

Full Text

Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity

E Kostareli, M Gounari, A Janus, F Murray, X Brochet, V Giudicelli, S Pospisilova, D Oscier, L Foroni, P F di Celle, B Tichy, L B Pedersen, J Jurlander, M Ponzoni, A Kouvatsi, A Anagnostopoulos, K Thompson, N Darzentas, M-P Lefranc, C Belessi, R Rosenquist, F Davi, P Ghia and K Stamatopoulos

Leukemia 2012 26: 1127-1131; advance online publication, November 4, 2011; 10.1038/leu.2011.311

Full Text

AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemia

J Dunne, D Mannari, T Farzaneh, A Gessner, F W van Delft, O Heidenreich, B D Young and D M Gascoyne

Leukemia 2012 26: 1131-1135; advance online publication, November 8, 2011; 10.1038/leu.2011.316

Full Text

SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients

T L Lasho, C M Finke, C A Hanson, T Jimma, R A Knudson, R P Ketterling, A Pardanani and A Tefferi

Leukemia 2012 26: 1135-1137; advance online publication, November 8, 2011; 10.1038/leu.2011.320

Full Text

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

F Damm, F Thol, O Kosmider, S Kade, P Löffeld, F Dreyfus, A Stamatoullas-Bastard, A Tanguy-Schmidt, O Beyne-Rauzy, S de Botton, A Guerci-Bresler, G Göhring, B Schlegelberger, A Ganser, O A Bernard, M Fontenay and M Heuser

Leukemia 2012 26: 1137-1140; advance online publication, November 8, 2011; 10.1038/leu.2011.321

Full Text

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors

E Traer, R MacKenzie, J Snead, A Agarwal, A M Eiring, T O'Hare, B J Druker and M W Deininger

Leukemia 2012 26: 1140-1143; advance online publication, November 18, 2011; 10.1038/leu.2011.325

Full Text

Oral high-dose glucocorticoids and Ofatumumab in fludarabine-resistant Chronic Lymphocytic Leukemia

D E Spaner

Leukemia 2012 26: 1144-1145; advance online publication, November 8, 2011; 10.1038/leu.2011.329

Full Text

Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis

O Meynet, M Bénéteau, M A Jacquin, L A Pradelli, A Cornille, M Carles and J-E Ricci

Leukemia 2012 26: 1145-1147; advance online publication, November 11, 2011; 10.1038/leu.2011.327

Full Text

Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?

G Barosi, A Tefferi and T Barbui on behalf of the ad hoc committee ‘Definition of clinically relevant outcomes for contemporarily clinical trials in Ph-neg MPNs’

Leukemia 2012 26: 1148-1149; advance online publication, November 22, 2011; 10.1038/leu.2011.337

Full Text

Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cells

J Tanaka, J Sugita, S Shiratori, A Shigematu, S Asanuma, K Fujimoto, M Nishio, T Kondo and M Imamura

Leukemia 2012 26: 1149-1152; advance online publication, December 6, 2011; 10.1038/leu.2011.345

Full Text

Corrigendum

Top

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

S K Kumar, J H Lee, J J Lahuerta, G Morgan, P G Richardson, J Crowley, J Haessler, J Feather, A Hoering, P Moreau, X LeLeu, C Hulin, S K Klein, P Sonneveld, D Siegel, J Bladeé, H Goldschmidt, S Jagannath, J S Miguel, R Orlowski, A Palumbo, O Sezer and S V Rajkumar BGM Durie on behalf of the International Myeloma Working Group

Leukemia 2012 26: 1153; 10.1038/leu.2012.15

Full Text

Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC

T Holien, T K Våtsveen, H Hella, C Rampa, G Brede, L A G Grøseth, M Rekvig, M Børset, T Standal, A Waage and A Sundan

Leukemia 2012 26: 1154; 10.1038/leu.2012.64

Full Text

Advertisement
Leukemia SPOTLIGHTS - focusing on topical research in the field of leukemia and allied diseases.

Have you read the latest collections?

miRNA and Hematopoiesis
Guest Editor: Dr. Monique L. den Boer

Signaling pathways regulating HSC
Guest Editor: Prof. F Staal

Explore the full series at www.nature.com/leu/spotlights
 
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group
 

No comments: